Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial-Reference-Cited by-同舟云学术

Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial

Published:2019-10 Issue:10 Volume:19 Page:1080-1090
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

O'Riordan William,Cardenas Carrie,Shin Elliot,Sirbu Alissa,Garrity-Ryan Lynne,Das Anita F,Eckburg Paul B,Manley Amy,Steenbergen Judith N,Tzanis Evan,McGovern Paul C,Loh Evan

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference34 articles.

1. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections;Russo;Clin Microbiol Infect,2016

2. Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact;Kaye;PLoS One,2015

3. Trends in US hospital admissions for skin and soft tissue infections;Edelsberg;Emerg Infect Dis,2009

4. The economic burden of community-associatded methicillin-resistant Staphylococcus aureus (CA-MRSA);Lee;Clin Microbiol Infect,2013

5. Potential cost-savings with once-daily aminomethylcycline antibiotic versus vancomycin in hospitalized patients with acute bacterial skin and skin structure infections;LaPenssee;Am Health Drug Benefits,2018

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections;Antimicrobial Agents and Chemotherapy;2024-09-04

2. Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities;European Journal of Medicinal Chemistry;2024-04

3. Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials;BMC Infectious Diseases;2024-02-19

4. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database;Frontiers in Pharmacology;2024-02-16

5. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022;Microbiology Spectrum;2024-01-11